Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ADMA Biologics Inc (ADMA : NSDQ)
 
 • Company Description   
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Number of Employees: 647

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.28 Daily Weekly Monthly
20 Day Moving Average: 9,310,659 shares
Shares Outstanding: 238.16 (millions)
Market Capitalization: $2,210.12 (millions)
Beta: 0.82
52 Week High: $25.67
52 Week Low: $7.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -41.30% -39.67%
12 Week -48.24% -45.38%
Year To Date -49.12% -47.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
465 STATE ROUTE 17
-
RAMSEY,NJ 07446
USA
ph: 201-478-5552
fax: 201-478-5553
adma@argotpartners.com http://www.admabiologics.com
 
 • General Corporate Information   
Officers
Adam S. Grossman - President; Chief Executive Officer and Director
Steven A. Elms - Chairman
Jerrold B. Grossman - Vice Chairman
Brad Tade - Chief Financial Officer
Alison Finger - Director

Peer Information
ADMA Biologics Inc (CORR.)
ADMA Biologics Inc (RSPI)
ADMA Biologics Inc (CGXP)
ADMA Biologics Inc (BGEN)
ADMA Biologics Inc (GTBP)
ADMA Biologics Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 000899104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/06/26
Share - Related Items
Shares Outstanding: 238.16
Most Recent Split Date: (:1)
Beta: 0.82
Market Capitalization: $2,210.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.95 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.72
Trailing 12 Months: 14.28
PEG Ratio: -
Price Ratios
Price/Book: 4.62
Price/Cash Flow: 14.19
Price / Sales: 4.33
EPS Growth
vs. Year Ago Period: 42.86%
vs. Previous Quarter: 25.00%
Sales Growth
vs. Year Ago Period: 18.39%
vs. Previous Quarter: 3.68%
ROE
03/31/26 - -
12/31/25 - 37.52
09/30/25 - 36.52
ROA
03/31/26 - -
12/31/25 - 27.87
09/30/25 - 26.65
Current Ratio
03/31/26 - -
12/31/25 - 6.71
09/30/25 - 7.13
Quick Ratio
03/31/26 - -
12/31/25 - 3.74
09/30/25 - 3.65
Operating Margin
03/31/26 - -
12/31/25 - 30.90
09/30/25 - 29.00
Net Margin
03/31/26 - -
12/31/25 - 28.80
09/30/25 - 42.87
Pre-Tax Margin
03/31/26 - -
12/31/25 - 35.80
09/30/25 - 31.89
Book Value
03/31/26 - -
12/31/25 - 2.01
09/30/25 - 1.81
Inventory Turnover
03/31/26 - -
12/31/25 - 1.13
09/30/25 - 1.21
Debt-to-Equity
03/31/26 - -
12/31/25 - 0.16
09/30/25 - 0.18
Debt-to-Capital
03/31/26 - -
12/31/25 - 13.73
09/30/25 - 15.56
 

Powered by Zacks Investment Research ©